By Flavia Fortes and Jenna Ebersole ( April 27, 2021) -- The clearance of AstraZeneca’s acquisition of Alexion by the Federal Trade Commission shows that large pharmaceutical deals can still escape lengthy scrutiny during the Biden administration despite promises for tougher enforcement....